


Linvencorvir

Chemical Properties

CAS No. :	1808248-05-6
Formula:	C ₂₉ H ₃₅ FN ₆ O ₅ S
Molecular Weight:	598.69
Storage:	Powder: -20°C for 3 years In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.



Biological Description

Description	Linvencorvir is a hepatitis B virus (HBV) core protein variant modifier used to treat chronic HBV infection.
Targets(IC50)	Apoptosis, Antibiotic, HBV
In vivo	Linvencorvir (RO7049389) (600/1000mg; oral; Caucasian and Asian, male and female) followed by 100µg intravenous [13 C]RO7049389. The model performance in predicting the pharmacokinetic profiles of RO7049389 aligned with clinical observations in Caucasians and was also successfully applied to Asians. Accordingly, the drug disposition pathways for RO7049389 were postulated with newly characterized estimates of the fractions: biliary excretion by P-glycoprotein (~41%), direct glucuronidation via uridine 5'-diphosphoglucuronosyltransferase 1A3 (~11%), hexose conjugation (~6%), oxidation by CYP3A4 (~28%) and other oxidation reactions (~9%). These results support the ongoing clinical development program for RO7049389 and highlight the broader value of PBPK and MB analyses in drug development.[3]

Solubility Information

Solubility	DMSO: 128.8 mg/mL (215.14 mM), Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	--

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.6703 mL	8.3516 mL	16.7031 mL
5 mM	0.3341 mL	1.6703 mL	3.3406 mL
10 mM	0.167 mL	0.8352 mL	1.6703 mL
50 mM	0.0334 mL	0.167 mL	0.3341 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

WHO. International Nonproprietary Names for Pharmaceutical Substances (INN). WHO Drug Information. 2021;35(4):1017

Zhang W, et al. Discovery of Lincovir (RG7907), a Hepatitis B Virus Core Protein Allosteric Modulator, for the Treatment of Chronic HBV Infection. J Med Chem. 2023;66(6):4253-4270.

Zhang Y, et al. Evaluation of the drug disposition of RO7049389 with in vitro data and human mass balance supported by physiologically based pharmacokinetic modelling [published online ahead of print, 2023 Jun 1]. Br J Clin Pharmacol.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481